Last reviewed · How we verify
Sorafenib - Period 1
At a glance
| Generic name | Sorafenib - Period 1 |
|---|---|
| Also known as | Regimen A (reference) |
| Sponsor | Xspray Pharma AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (PHASE2)
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (PHASE2)
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (PHASE2)
- TDM for Optimized Outcome in Patients With mRCC.
- Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy (PHASE2)
- Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects (PHASE1)
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (PHASE2, PHASE3)
- CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib - Period 1 CI brief — competitive landscape report
- Sorafenib - Period 1 updates RSS · CI watch RSS
- Xspray Pharma AB portfolio CI